Collecting data on bone and soft tissue tumors
Official title: Single-center Real World Prospective Observational Study of Clinical Features, Treatment Patterns, and Survival of Bone and Soft Tissue Tumors
Run by Henan Cancer Hospital · NCT05468970 · Data updated 2026-11-12
This study is collecting information from patients with bone and soft tissue tumors at Henan Cancer Hospital over the next ten years to see how their treatment and outcomes change over time.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 6 Years to 99 Years |
| Sex | All |
| Enrollment | 6000 (estimated) |
| Sponsor | Henan Cancer Hospital Government |
| Locations | 1 site (Zhengzhou, Henan) |
| Status | Recruiting |
| Started | August 3, 2022 |
| Main results expected | July 31, 2032 |
| Study ends | July 31, 2032 |
| Registry record updated | September 1, 2023 |
| Trial ID | NCT05468970 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients of all ages with a confirmed pathological diagnosis of bone and soft tissue tumors who have been hospitalized at Henan Cancer Hospital.
✕Probably not a fit
Patients without a definite pathology diagnosis will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to prospectively gather and analyze real-world clinical data from patients with bone and soft tissue tumors treated at Henan Cancer Hospital over the next ten years. The focus is on evaluating changes in clinical characteristics, treatment patterns, and survival outcomes of these patients. By collecting comprehensive information on treatment methods and prognostic factors, the study seeks to provide valuable insights for future clinical treatment and research in this area.
Why it matters
Potential benefit: If successful, this study could enhance understanding of bone and soft tissue tumors, leading to improved treatment strategies and patient outcomes.
How similar studies have gone: While this approach is observational and builds on existing knowledge, similar studies have successfully contributed to understanding treatment patterns and outcomes in oncology.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: All ages, male and female. The pathological diagnosis of BSTS in our hospital was a subtype. Has received at least one hospitalization in this hospital. The target lesions could be evaluated according to the efficacy evaluation criteria of solid tumor (RECIST; Version 1.1) Measure diameter changes. Exclusion Criteria: No definite pathology.
Where it's running
-
Department of Bone and Soft Tissue ,Henan Cancer Hospital
Zhengzhou, Henan, China Recruiting
Study contacts
- Study coordinator: Wang Jiaqiang, Dr.
- Email: wjqwtj@126.com
- Phone: 13592413731
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gene-based grouping of bone and soft tissue tumors
This study tests whether tumors of bone and soft tissue can be sorted into clearer genetic groups using DNA and RNA data.
-
Patient-derived 3D tumor models for sarcoma and metastases
This project will try to turn leftover tumor and blood samples from people with sarcoma or with bone or lung metastases into lab-grown 3D tumor models to help test new treatments.
-
QL1706 treatment for advanced bone and soft tissue sarcoma
This will try QL1706 in adults with advanced or metastatic bone and soft tissue sarcomas to see if it controls tumor growth and is well tolerated.
-
New drug delivery method for treating sarcoma
This study is testing a new way to deliver cancer treatment directly to hard-to-reach sarcoma tumors using tiny particles and light to see if it works better for patients with inoperable tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.